%0 Journal Article %T Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma %+ Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10) %+ Site de Recherche Intégrée sur le Cancer - SIRIC « ILIAD » [Nantes] %+ Centre hospitalier universitaire de Nantes (CHU Nantes) %+ Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11) %A Touzeau, Cyrille %A Antier, Chloé %A Moreau, Philippe %< avec comité de lecture %@ 1479-6694 %J Future Oncology %I Future Medicine %V 17 %N 9 %P 993-998 %8 2021-03 %D 2021 %R 10.2217/fon-2020-0907 %M 33289427 %K carfilzomib %K daratumumab %K lenalidomide %K monoclonal antibody %K myeloma %K proteasome inhibitor %Z Life Sciences [q-bio]/CancerJournal articles %X The therapeutic landscape of relapsed multiple myeloma (MM) is constantly evolving. To date, a large proportion of patients present with lenalidomide refractory disease at the time of first or second relapse. In this context, few efficient options are currently available. Carfilzomib and daratumumab are approved in the relapse setting. Recently, Phase Ib and Phase III trials evaluated the triplet drug combination daratumumab–carfilzomib–dexamethasone in the relapse setting and demonstrated strong clinical efficacy, especially in lenalidomide refractory patients. Based on these results, this combination has been approved by the US FDA for relapsed MM patients. The present review discusses the safety and efficacy of daratumumab–carfilzomib–dexamethasone in MM. %G English %L inserm-03496299 %U https://inserm.hal.science/inserm-03496299 %~ INSERM %~ UNIV-NANTES %~ CNRS %~ UNIV-ANGERS %~ LORIA2 %~ CRCINA %~ TEST-HALCNRS %~ NANTES-UNIVERSITE %~ UNIV-NANTES-AV2022